1. Home
  2. DT vs RDY Comparison

DT vs RDY Comparison

Compare DT & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dynatrace Inc.

DT

Dynatrace Inc.

HOLD

Current Price

$41.14

Market Cap

10.7B

Sector

Technology

ML Signal

HOLD

Logo Dr. Reddy's Laboratories Ltd

RDY

Dr. Reddy's Laboratories Ltd

HOLD

Current Price

$13.59

Market Cap

11.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DT
RDY
Founded
2005
1984
Country
United States
India
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.7B
11.6B
IPO Year
2019
2001

Fundamental Metrics

Financial Performance
Metric
DT
RDY
Price
$41.14
$13.59
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
26
1
Target Price
$51.77
$16.90
AVG Volume (30 Days)
6.3M
3.0M
Earning Date
05-13-2026
05-12-2026
Dividend Yield
N/A
0.52%
EPS Growth
N/A
N/A
EPS
0.54
N/A
Revenue
$2,018,387,000.00
N/A
Revenue This Year
$21.74
$7.72
Revenue Next Year
$14.85
$3.50
P/E Ratio
$81.15
$18.67
Revenue Growth
18.82
N/A
52 Week Low
$31.64
$12.19
52 Week High
$57.55
$16.17

Technical Indicators

Market Signals
Indicator
DT
RDY
Relative Strength Index (RSI) 60.58 52.79
Support Level $32.88 $12.90
Resistance Level $46.56 $14.04
Average True Range (ATR) 1.67 0.26
MACD 0.20 0.05
Stochastic Oscillator 97.44 81.87

Price Performance

Historical Comparison
DT
RDY

About DT Dynatrace Inc.

Dynatrace is a software-as-a-service company that enables customers to monitor and analyze their information technology infrastructure, from servers to applications and Python scripts. Dynatrace's unified platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to optimize their business for service-level objectives and ensure uptime.

About RDY Dr. Reddy's Laboratories Ltd

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Share on Social Networks: